SavedAdd your journal

Journals / Türk Klinik Biyokimya Dergisi / 2016 / Cilt: 14 - Sayı: 2

Monitoring Anti-platelet Therapy with Platelet Function Testing

Antitrombositik Tedavi İzleminde Trombosit Fonksiyon Testleri

Burcu BARUTÇUOĞLU
Pages
144–155
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review article, platelet activation, formation of thrombosis, up-to-date platelet function tests and drug resistance in patients receiving anti-platelet drugs will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:It is known that anti-platelet drugs reduce the vascular pathologies in patients with cardiovascular disease.
📊
Key Findings & Data:Despite using these drugs there are still a number of patients suffering from vascular events.
💡
Conclusion & Impact:In this review article, platelet activation, formation of thrombosis, up-to-date platelet function tests and drug resistance in patients receiving anti-platelet drugs will be discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

It is known that anti-platelet drugs reduce the vascular pathologies in patients with cardiovascular disease. Despite using these drugs there are still a number of patients suffering from vascular events. Even though monitoring antiplatelet drug therapy with platelet function tests is contentious, they are widely in use. The wide variety of available platelet function tests using different methodologies, the apparent lack of standardization, and emerging evidence on the clinical value of platelet function testing are resulting in a considerable uncertainty in the clinical practice, Nevertheless, platelet function testing has clinical benefits for the patients and also helps in identifying the right drug at the right dose for the right patient. In this review article, platelet activation, formation of thrombosis, up-to-date platelet function tests and drug resistance in patients receiving anti-platelet drugs will be discussed.

Özet

Kardiyovasküler hastalarda antitrombositik ilaçların damarsal patolojileri azalttığı, bazı hastalarda ise antitrombositik tedaviye rağmen vasküler olay yaşayan hastaların olduğu bilinmektedir. Trombosit fonksiyon testlerinin antitrombositik tedavi izleminde kullanımı tartışmalı olsa da antitrombositik tedavi izleminde yaygın olarak kullanılmaktadır. Günümüzde çeşitli ölçüm metodları kullanan birçok trombosit fonksiyon test cihazı bulunmaktadır. Ancak farklı metodların kullanılması, standardizasyonun sağlanamaması ve hastaların klinik durumunu her zaman tam olarak yansıtamaması bu testlerin klinik uygulamalarda oldukça önemli kuşkular doğurmasına neden olmaktadır. Yinede trombosit fonksiyon testleri hastalarda uygun antitrombositik ilaç seçimine, uygun dozun ayarlamasına yardımcı olur. Bu derlemede trombosit aktivasyonu ve trombositlerin trombüs oluşumundaki yeri, güncel trombosit fonksiyon testleri ve antitrombositik tedavi gören hastalarda gelişen ilaç direnci ele alınacaktır.

🔖

Cite This Article

BARUTÇUOĞLU, B. (2022). Monitoring Anti-platelet Therapy with Platelet Function Testing. Türk Klinik Biyokimya Dergisi, Cilt: 14 - Sayı: 2, 144–155. https://ajindex.com/articles/634414

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Lippi G, Favaloro EJ, Salvagno GL, Franchini M. Laboratory assessment of perioperative management of patients on anitplatelet therapy: From bench to the bedside. Clinica Chimica Acta 2009;405.8-16
  2. Paniccia R, Priora R, Liotta AA, Abbate R. Platelet function tests: a comperative review. Vascular health and risk management 2015;11:133-148
  3. Miller JL, Rao AK. Blood platelets and von Willebrand disease. McPherason RA, Pincus MR. Henry's Clinical Diagnosis and Management by Laboratory Methods. 22 Ed. Philadelphia,ElseiverSaunders, 2011, chapter 40, 801-822
  4. Kereiakes DJ, Gurbel PA. Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. J. Am. Coll. Cardiol. Intv. 2008;1;111-121
  5. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34:58-73
  6. Şahna E. Antitrombositik ilaçlar. Türkiye Kliniklari J Cardiol-Special Topics. 2009;2-5:67-85
  7. Katzung B: Basic and Clinical Pharmacology
  8. Ed. San Francisco. The Mcgraw-Hill Companies. 2003, 543-550
  9. Cannon CP. Brounwald E. Unstable angina and non-ST elevation myocardial Infarction. In Zipes Dp, Libby P, Bonow RO, Braunwald E. Editors. Braunwald's Heart Disease. 7th ed. Philadelphia: Saunders. 2005, 1243-79
  10. Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol 2006;19:439-448
  11. Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5(Suppl. 1):230-237
  12. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug 'resistance'. Part 1:mechanisms and clinical measurements. Nat. Rev. Cardiol 2009; 6, 273-282
  13. Kuliczkowski W, Witkowski A, Polonski L, et al. Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society,endorsed by the Working Group on Thrombosis of the European Society of Cardiology. European Heart Journal 2009; 30, 426- 435
  14. Harrison P, Mackie I, Mumford A, et al. Guidelines for the Laboratory Investigation of Heritable Disorders of Platelet Function. BCSH guideline. 2011:1-41
  15. Kottke-Marchant, Corcoran G. The laboratory diagnosis of platelet disorders. Arch Pathol Lab Med 2002;126:133-146 15. Rodgers, RP, Levin, J A critical reappraisal of the bleeding time. Semin. Thr